

Ref: EPL/CS/SE/0039/2025**Date:** June 02, 2025

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai - 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Acquisition

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we would like to inform that Emcure Pharmaceuticals Limited ("Emcure"), has entered into a Share Subscription and Shareholders' Agreement and Power Transfer Agreement(s) dated June 02, 2025.

The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the Listing Regulations are provided in **Annexure A**, enclosed herewith.

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

Chetan Sharma
Company Secretary & Compliance Officer
Membership Number: F8352

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 - 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

Annexure A**Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:**

Sr. No	Particulars	Information
a)	Name of the target entity, details in brief such as size, turnover etc.	<p>Torrent Urja 37 Private Limited, having CIN: U20123GJ2025PTC158014 and registered office at Samanvay, 600, Tapovan, Ambawadi, Manekbag, Ahmedabad- 380015, Gujarat, India ("TUPL").</p> <p>TUPL is a wholly owned subsidiary of Torrent Green Energy Private Limited, having CIN: U35105GJ2023PTC143527 ("TGEPL").</p> <p><u>Details of TUPL:</u></p> <p>Authorized Share Capital: Rs. 5,00,000 (Rupees Five Lakhs) divided into 50,000 (Fifty Thousand) Equity Shares having face value of Rs. 10/- (Rupees Ten) each.</p> <p>Paid-up Share Capital: Rs. 5,00,000 (Rupees Five Lakhs) divided into 50,000 (Fifty Thousand) Equity Shares having face value of Rs. 10/- (Rupees Ten) each.</p> <p>The First Annual General Meeting of TUPL is due to be held, hence details of turnover, PAT etc., are unavailable.</p>
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No, the transaction is not a related party transaction and promoter / promoter group does not have any interest in the entity whose securities are being acquired.
c)	Industry to which the entity being acquired belongs	Renewable Energy
d)	Objects and impacts of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside	TGEPL is one of India's leading power generation and utility company, engaged in renewable and conventional modes of power generation, distribution and power trading. Its subsidiary, TUPL is in the process of

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

	the main line of business of the listed entity)	<p>setting up a ground mounted solar (photovoltaic) power generation facility at the sites, having a capacity of 11.27 MWp, which will be set up as a captive power Project in accordance with the Applicable Laws.</p> <p>Emcure has entered into two Power Transfer Agreement(s) dated June 02, 2025, to purchase the electricity generated from TUPL, in accordance with the provisions of the aforesaid Agreement(s) to meet its energy requirements at identified facilities in the state of Gujarat.</p>
e)	Brief details of any governmental or regulatory approvals required for the acquisition	Nil
f)	Indicative time period for completion of the acquisition	The completion of the acquisition is subject to the receipt of all consents, permissions required to be obtained by TUPL from regulatory authority for open access for captive consumption of electricity.
g)	Nature of consideration - whether cash consideration or share swap and details of the same	Cash Consideration
h)	Cost of acquisition or the price at which the shares are acquired	Rs. 3,71,87,740/-
i)	Percentage of shareholding/ control acquired and/ or number of shares acquired	At least 26% of the paid-up share capital (on fully diluted basis) of TUPL
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<ol style="list-style-type: none"> 1. Background: TUPL, incorporated on January 20, 2025, is a privately held company based in Ahmedabad, Gujarat. It is primarily engaged in the business of generation and supply of electricity from renewable energy resources. 2. Products / line of business: Renewable Energy sector 3. Date of incorporation: January 20, 2025 4. Last 3 years' turnover: Not Applicable 5. Country of operation: India

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251